pirenzepine has been researched along with Depression in 16 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression." | 9.10 | Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. ( Baker, RW; Beymer, K; Bowden, C; Breier, A; Calabrese, J; Centorrino, F; Dube, S; Evans, AR; Ketter, TA; Mitchell, PB; Risser, R; Sachs, G; Tohen, M; Tollefson, GD; Vieta, E, 2003) |
| "In a 6-week placebo- and haloperidol (HAL)-controlled trial with 335 randomized subjects with chronic schizophrenia in an acute exacerbation, three fixed dose ranges of OLZ (5, 10, or 15 +/- 2." | 9.08 | A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. ( Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV, 1998) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 8.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 7.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "The aim was to describe the short-term (6 months) effects of olanzapine on behavioral and motor clinical manifestations in a group of 11 patients with Huntington disease." | 7.71 | Short-term effects of olanzapine in Huntington disease. ( Brusa, L; Cannella, M; Porcellini, A; Ruggieri, S; Simonelli, M; Squitieri, F, 2001) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression." | 5.10 | Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. ( Baker, RW; Beymer, K; Bowden, C; Breier, A; Calabrese, J; Centorrino, F; Dube, S; Evans, AR; Ketter, TA; Mitchell, PB; Risser, R; Sachs, G; Tohen, M; Tollefson, GD; Vieta, E, 2003) |
| " In this post hoc analysis of the Brief Psychiatric Rating Scale anxiety-depression cluster, olanzapine therapy was associated with a significantly greater baseline-to-end-point improvement in the cluster compared with haloperidol therapy among 1996 randomized, double-blind subjects." | 5.09 | Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? ( Sanger, TM; Tollefson, GD, 1999) |
| "In a 6-week placebo- and haloperidol (HAL)-controlled trial with 335 randomized subjects with chronic schizophrenia in an acute exacerbation, three fixed dose ranges of OLZ (5, 10, or 15 +/- 2." | 5.08 | A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. ( Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV, 1998) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 4.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 3.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "The aim was to describe the short-term (6 months) effects of olanzapine on behavioral and motor clinical manifestations in a group of 11 patients with Huntington disease." | 3.71 | Short-term effects of olanzapine in Huntington disease. ( Brusa, L; Cannella, M; Porcellini, A; Ruggieri, S; Simonelli, M; Squitieri, F, 2001) |
| "Schizophrenia is also associated with aggression directed at self and others." | 2.41 | The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. ( Keck, PE; McElroy, SL; Strakowski, SM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sattar, SP | 1 |
| Gastfriend, DR | 1 |
| Lane, HY | 1 |
| Guo, SC | 1 |
| Hwang, TJ | 1 |
| Chen, YS | 1 |
| Cheng, JJ | 1 |
| Lee, YC | 1 |
| Hong, CJ | 1 |
| Hwu, HG | 1 |
| Chang, WH | 1 |
| Gothelf, D | 1 |
| Apter, A | 1 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 1 |
| Weizman, R | 1 |
| Ratzoni, G | 1 |
| Tohen, M | 1 |
| Vieta, E | 1 |
| Calabrese, J | 1 |
| Ketter, TA | 1 |
| Sachs, G | 1 |
| Bowden, C | 1 |
| Mitchell, PB | 1 |
| Centorrino, F | 1 |
| Risser, R | 1 |
| Baker, RW | 1 |
| Evans, AR | 1 |
| Beymer, K | 1 |
| Dube, S | 1 |
| Tollefson, GD | 4 |
| Breier, A | 2 |
| Feldman, PD | 1 |
| Kaiser, CJ | 1 |
| Kennedy, JS | 1 |
| Sutton, VK | 1 |
| Tran, PV | 2 |
| Zhang, F | 1 |
| Slotkin, TA | 1 |
| Seidler, FJ | 1 |
| Sanger, TM | 2 |
| Beasley, CM | 1 |
| Walker, Z | 1 |
| Grace, J | 1 |
| Overshot, R | 1 |
| Satarasinghe, S | 1 |
| Swan, A | 1 |
| Katona, CL | 1 |
| McKeith, IG | 1 |
| Chau, D | 1 |
| Rada, PV | 1 |
| Kosloff, RA | 1 |
| Hoebel, BG | 1 |
| Keck, PE | 1 |
| Strakowski, SM | 1 |
| McElroy, SL | 1 |
| Shad, MU | 1 |
| Marsh, C | 1 |
| Preskorn, SH | 1 |
| Bhana, N | 1 |
| Foster, RH | 1 |
| Olney, R | 1 |
| Plosker, GL | 1 |
| Squitieri, F | 1 |
| Cannella, M | 1 |
| Porcellini, A | 1 |
| Brusa, L | 1 |
| Simonelli, M | 1 |
| Ruggieri, S | 1 |
| Nieman, DH | 1 |
| Koelman, JH | 1 |
| Linszen, DH | 1 |
| Bour, LJ | 1 |
| Dingemans, PM | 1 |
| Ongerboer de Visser, BW | 1 |
| Coiro, V | 1 |
| Volpi, R | 1 |
| Capretti, L | 1 |
| Speroni, G | 1 |
| Castelli, A | 1 |
| Mosti, A | 1 |
| Marchesi, C | 1 |
| Gardini, E | 1 |
| Rossi, G | 1 |
| Chiodera, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
2 reviews available for pirenzepine and Depression
| Article | Year |
|---|---|
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Depression; | 2000 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition | 2001 |
4 trials available for pirenzepine and Depression
| Article | Year |
|---|---|
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Dru | 2003 |
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Diso | 2003 |
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Benzodiazepines; Depression; Dose-Response Relationship, Drug; | 1998 |
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Topics: Antipsychotic Agents; Anxiety; Benzodiazepines; Brief Psychiatric Rating Scale; Depression; Double-B | 1999 |
10 other studies available for pirenzepine and Depression
| Article | Year |
|---|---|
Visual inspection of medications in preventing unexplained relapses.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Aspirin; Benzodiazepines; Cetirizine; Clonazepam | 2002 |
Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Depression; Female; Humans; Male; Middle Aged; Olanzap | 2002 |
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depression; Double | 2003 |
Cholinergic receptor subtypes in the olfactory bulbectomy model of depression.
Topics: Alkaloids; Animals; Azocines; Brain; Depression; Disease Models, Animal; Gene Expression Regulation; | 2006 |
Olanzapine in dementia with Lewy bodies: a clinical study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Contraindicatio | 1999 |
Cholinergic, M1 receptors in the nucleus accumbens mediate behavioral depression. A possible downstream target for fluoxetine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acetylcholine; Animals; Arecoline; Depression; Female; Fluox | 1999 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Halo | 2001 |
Short-term effects of olanzapine in Huntington disease.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Anxiety; Benzodiazepines; Depression; Femal | 2001 |
Clinical and neuropsychological correlates of the P300 in schizophrenia.
Topics: Adult; Benzodiazepines; Depression; Event-Related Potentials, P300; Female; Humans; Male; Neuropsych | 2002 |
Simultaneous inhibition by pirenzepine of the GH responses to GnRH and TRH in insulin-dependent diabetics and in patients with major depression.
Topics: Acetylcholine; Adult; Depression; Diabetes Mellitus, Type 1; Growth Hormone; Humans; Male; Pirenzepi | 1989 |